BPC-157 TB-500 Dosage as Recorded in Animal Studies

BPC-157 and TB-500 Dosage in the Research Literature

BPC-157 TB-500 dosage has no validated human figure, and none for the blend as a unit. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — for example a 10 mg BPC-157 + 10 mg TB-500 pairing — but no peer-reviewed combination dose-finding study exists to support any such ratio ^[9]. Everything below is BPC-157 and TB-500 dosage in animal models, expressed as the studies expressed it.

The BPC-157 constituent has been studied in rodents at doses expressed per body weight, frequently around 10 µg/kg and 10 ng/kg in the transected-tendon work ^[1], with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats. The TB-500 / Thymosin Beta-4 constituent spans a wide range in animal work — for example 150 µg twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study, and a 2-18 mg/kg range in a rat embolic-stroke dose-response study where the highest dose gave no benefit ^[4]. None of these is human guidance; each is a species- and model-specific research parameter.

Half-Life and Pharmacokinetics

No validated human pharmacokinetic half-life and pharmacokinetics exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[4][8].

This is a recurring gap: the human reference points that do exist belong to full-length Thymosin Beta-4, not to the seven-amino-acid fragment that is actually sold as TB-500 ^[8].

What is the half-life of BPC-157 and TB-500?

No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[4][8].

Administration Frequency in Research Protocols

There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example Thymosin Beta-4 at 150 µg twice weekly intraperitoneally for six months in one model ^[4]; community "loading then maintenance" protocols have no controlled-trial basis.

Routes Studied and Reconstitution

The predominant research-community routes for the blend are subcutaneous and intramuscular, but these are not drawn from controlled human efficacy trials ^[9]. In the underlying rodent efficacy studies, intraperitoneal administration predominates for both peptides ^[1][4]. Intravenous routes appear in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 safety pilot, and local, intra-lesional, and topical routes appear in individual-compound wound and tendon models ^[4].

Wolverine Injection: Routes Studied in Research

The research community most often discusses a wolverine injection by the subcutaneous or intramuscular route, but those routes reflect community practice, not controlled human efficacy trials ^[9]. The underlying rodent efficacy studies for both peptides predominantly used the intraperitoneal route ^[1][4].

BPC 157 TB 500 Oral vs Injected

BPC 157 TB 500 oral framing rests on BPC-157 being studied as a "stable gastric" peptide; injected routes dominate the TB-500 literature. Blend oral products are marketed but lack validated pharmacokinetics, and no controlled study compares oral against injected administration of the combination ^[9].

Reconstitution in Research Handling

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed ^[8]. This is research-handling context, not a human-use instruction.